GSK/Synta Elesclomol Analysis Shows Stronger Benefit In Treatment Naive Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Data is the basis for Phase III study design, with filing targeted for 2009.
You may also be interested in...
Synta Earns $25M Milestone From GSK For Melanoma Candidate
Partnered with GSK on elesclomol, Synta anticipates “go, no go” decision in late 2008 or early 2009.
Synta Earns $25M Milestone From GSK For Melanoma Candidate
Partnered with GSK on elesclomol, Synta anticipates “go, no go” decision in late 2008 or early 2009.
Medarex, BMS Stall Ipilimumab’s BLA
Timing for melanoma drug is uncertain after talks with FDA.